

Table A1: Pharmacokinetic sampling times and assays by cohort

Sampling Times		Cohort 1 (TQ + DHA-PQP)		Cohort 2 (TQ + AL)		Cohort 3 (DHA-PQP)		Cohort 4 (AL)		Cohort 5 (TQ)	
Day	Hour	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays
1	Pre-dose	2	A, B	2	A, C	1	B	1	C	1	A
	1	1	B	1	C	1	B	1	C		
	2	2	A, B	2	A, C	1	B	1	C	1	A
	4	1	B	1	C	1	B	1	C		
	6	2	A, B	2	A, C	1	B	1	C	1	A
	12	1	A	1	A					1	A
2	24	1	A	1	A					1	A
3	48	2	A, B	1	A	1	B			1	A
	48.5	1	B			1	B				

Sampling Times		Cohort 1 (TQ + DHA-PQP)		Cohort 2 (TQ + AL)		Cohort 3 (DHA-PQP)		Cohort 4 (AL)		Cohort 5 (TQ)	
Day	Hour	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays
	49	1	B			1	B				
	49.5	1	B			1	B				
	50	1	B			1	B				
	51	1	B			1	B				
	52	1	B			1	B				
	54	1	B			1	B				
	56	1	B			1	B				
	60	2	A, B	2	A, C	1	B	1	C	1	A
	60.5			1	C			1	C		
	61			1	C			1	C		
	61.5			1	C			1	C		

Sampling Times		Cohort 1 (TQ + DHA-PQP)		Cohort 2 (TQ + AL)		Cohort 3 (DHA-PQP)		Cohort 4 (AL)		Cohort 5 (TQ)	
Day	Hour	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays
	62			1	C			1	C		
	64			1	C			1	C		
4	66			1	C			1	C		
	68			1	C			1	C		
	72	2	A, B	2	A, C	1	B	1	C	1	A
7	-	2	A, B	2	A, C	1	B	1	C	1	A
14	-	2	A, B	2	A, C	1	B	1	C	1	A
21	-	2	A, B	2	A, C	1	B	1	C	1	A
28	-	2	A, B	2	A, C	1	B	1	C	1	A
56	-	2	A, B	1	A	1	B	-	-	1	A
Σ # samples		34		31		21		18		13	

Sampling Times		Cohort 1 (TQ + DHA-PQP)		Cohort 2 (TQ + AL)		Cohort 3 (DHA-PQP)		Cohort 4 (AL)		Cohort 5 (TQ)	
Day	Hour	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays	# 2mL blood samples	Assays
Σ # draws		23		22		21		18		13	

Plasma assays:

A = tafenoquine (TQ)

B = piperazine (PQP), dihydroartemisinin (DHA)

C = artemether (A), dihydroartemisinin (DHA), lumefantrine (L).

T

Table A2: Change from baseline QTcF treatment difference for the interaction of tafenoquine with dihydroartemisinin-piperaquine

Time point	Difference for (tafenoquine + dihydroartemisinin-piperaquine) – dihydroartemisinin-piperaquine (90% CI)
12 h	5.63 (0.76, 10.51)
24 h	4.55 (0.22, 8.89)
36 h	3.22 (-2.21, 8.64)
48 h	5.63 (0.38, 10.89)
52 h	3.80 (-3.59, 11.20)
60 h	4.06 (-1.95, 10.07)
72 h	4.01 (-1.18, 9.20)
Day 7	3.38 (-1.45, 8.22)
Day 14	2.30 (-3.84, 8.44)
Day 28	-1.14 (-6.40, 4.13)
Day 56	1.15 (-2.99, 5.29)